# Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

> **NCT00657501** · PHASE3 · COMPLETED · sponsor: **BioSante Pharmaceuticals** · enrollment: 575 (actual)

## Conditions studied

- Hypoactive Sexual Desire Disorder

## Interventions

- **DRUG:** testosterone gel
- **DRUG:** placebo gel

## Key facts

- **NCT ID:** NCT00657501
- **Lead sponsor:** BioSante Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 575 (ACTUAL)
- **Last updated:** 2013-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00657501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00657501, "Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00657501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*